Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations.
Dutta S, Moritz J, Pregartner G, Thallinger GG, Brandstätter I, Lind K, Rezania S, Lyssy F, Reinisch A, Zebisch A, Berghold A, Wölfler A, Sill H. Dutta S, et al. Among authors: reinisch a. Ann Hematol. 2022 Apr;101(4):837-846. doi: 10.1007/s00277-022-04766-2. Epub 2022 Jan 26. Ann Hematol. 2022. PMID: 35083527 Free PMC article.
Sensitive and broadly applicable residual disease detection in acute myeloid leukemia using flow cytometry-based leukemic cell enrichment followed by mutational profiling.
Daga S, Rosenberger A, Kashofer K, Heitzer E, Quehenberger F, Halbwedl I, Graf R, Krisper N, Prietl B, Höfler G, Reinisch A, Zebisch A, Sill H, Wölfler A. Daga S, et al. Among authors: reinisch a. Am J Hematol. 2020 Oct;95(10):1148-1157. doi: 10.1002/ajh.25918. Epub 2020 Aug 10. Am J Hematol. 2020. PMID: 32602117 Free PMC article.
Micro-RNA-125a mediates the effects of hypomethylating agents in chronic myelomonocytic leukemia.
Berg JL, Perfler B, Hatzl S, Mayer MC, Wurm S, Uhl B, Reinisch A, Klymiuk I, Tierling S, Pregartner G, Bachmaier G, Berghold A, Geissler K, Pichler M, Hoefler G, Strobl H, Wölfler A, Sill H, Zebisch A. Berg JL, et al. Among authors: reinisch a. Clin Epigenetics. 2021 Jan 6;13(1):1. doi: 10.1186/s13148-020-00979-2. Clin Epigenetics. 2021. PMID: 33407852 Free PMC article.
EZH2 inactivation in RAS-driven myeloid neoplasms hyperactivates RAS-signaling and increases MEK inhibitor sensitivity.
Berg JL, Perfler B, Hatzl S, Uhl B, Reinisch A, Pregartner G, Berghold A, Penz T, Schuster M, Geissler K, Prokesch A, Müller-Tidow C, Hoefler G, Kashofer K, Wölfler A, Sill H, Caraffini V, Zebisch A. Berg JL, et al. Among authors: reinisch a. Leukemia. 2021 May;35(5):1521-1526. doi: 10.1038/s41375-021-01161-0. Epub 2021 Feb 15. Leukemia. 2021. PMID: 33589750 Free PMC article. No abstract available.
miR-23a mediates resistance to hypomethylating agents in myeloid neoplasms.
Mayer MC, Berg JL, Perfler B, Hatzl S, Herzog SA, Bachmaier G, Berghold A, Reinisch A, Wölfler A, Sill H, Zebisch A. Mayer MC, et al. Among authors: reinisch a. Ann Hematol. 2021 Nov;100(11):2845-2847. doi: 10.1007/s00277-021-04598-6. Epub 2021 Jul 22. Ann Hematol. 2021. PMID: 34291333 No abstract available.
Human gene-engineered calreticulin mutant stem cells recapitulate MPN hallmarks and identify targetable vulnerabilities.
Foßelteder J, Pabst G, Sconocchia T, Schlacher A, Auinger L, Kashofer K, Beham-Schmid C, Trajanoski S, Waskow C, Schöll W, Sill H, Zebisch A, Wölfler A, Thomas D, Reinisch A. Foßelteder J, et al. Among authors: reinisch a. Leukemia. 2023 Apr;37(4):843-853. doi: 10.1038/s41375-023-01848-6. Epub 2023 Feb 22. Leukemia. 2023. PMID: 36813992 Free PMC article.
101 results